Baxalta Incorporated (Baxalta) is a biopharmaceutical company with a portfolio of differentiated therapies that seek to address medical needs across various disease areas, including hemophilia, immunology and oncology. Baxalta's categories of products include Hemophilia products, such as Advate, Adynovate, Recombinate, Hemofil M, Immunate, Immunine, Rixubis and Prothromplex Total; Inhibitor Therapies products, including FEIBA and OBIZUR; Immunoglobulin Therapies products, which include GAMMAGARD LIQUID/KIOVIG, HYQVIA, GAMMAGARD S/D and SUBCUVIA; BioTherapeutics products, including FLEXBUMIN, BUMINATE, ARALAST NP, GLASSIA NP and CEPROTIN, and Oncology product, such as ONCASPAR. Baxalta Company develops, manufactures and markets a portfolio of treatments for hemophilia and other bleeding disorders, immune deficiencies, alpha-1 antitrypsin deficiency, burns and shock, and other chronic and acute medical conditions, as well as oncology treatments for acute lymphoblastic leukemia.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Biotechnology
- Sub-Industry: N/A
- Symbol: NYSE:BXLT
- CUSIP: N/A
- Web: N/A
- 50 Day Moving Avg: $46.02
- 200 Day Moving Avg: $46.02
- 52 Week Range: $37.44 - $46.52
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 18.12
- P/E Growth: 0.00
Frequently Asked Questions for Baxalta (NYSE:BXLT)
What is Baxalta's stock symbol?
Baxalta trades on the New York Stock Exchange (NYSE) under the ticker symbol "BXLT."
How were Baxalta's earnings last quarter?
Baxalta Inc (NYSE:BXLT) released its quarterly earnings results on Thursday, April, 28th. The company reported $0.47 earnings per share for the quarter, beating the Zacks' consensus estimate of $0.46 by $0.01. The business had revenue of $1.50 billion for the quarter, compared to analyst estimates of $1.47 billion. The company's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period in the prior year, the business earned $0.40 earnings per share. View Baxalta's Earnings History.
Who are some of Baxalta's key competitors?
Some companies that are related to Baxalta include Amgen (AMGN), Celgene (CELG), Gilead Sciences (GILD), Biogen (BIIB), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals Incorporated (VRTX), Grifols SA, Barcelona (GRFS), Incyte (INCY), Illumina (ILMN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Seattle Genetics (SGEN), Jazz Pharmaceuticals plc - (JAZZ), TESARO (TSRO), Alnylam Pharmaceuticals (ALNY), Exelixis (EXEL), BIO-TECHNE Corp (TECH) and Kite Pharma (KITE).
Who owns Baxalta stock?
Baxalta's stock is owned by a number of of institutional and retail investors. Top institutional investors include Tompkins Financial Corp (0.00%). Company insiders that own Baxalta stock include Albert P L Stroucken and Blake E Devitt. View Institutional Ownership Trends for Baxalta.
Who bought Baxalta stock? Who is buying Baxalta stock?
How do I buy Baxalta stock?
Shares of Baxalta can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Baxalta stock cost?
One share of Baxalta stock can currently be purchased for approximately $46.02.
Earnings History for Baxalta (NYSE:BXLT)Earnings History by Quarter for Baxalta (NYSE:BXLT)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|4/28/2016||Q116||$0.46||$0.47||$1.47 billion||$1.50 billion||View||N/A|
|2/16/2016||Q415||$0.56||$0.57||$1.71 billion||$1.80 billion||View||N/A|
|10/29/2015||Q315||$0.49||$0.56||$1.51 billion||$1.60 billion||View||Listen|
|7/30/2015||Q215||$0.50||$0.40||$1.41 billion||$1.47 billion||View||N/A|
Earnings Estimates for Baxalta (NYSE:BXLT)
Current Year EPS Consensus Estimate: $2.19 EPS
Next Year EPS Consensus Estimate: $2.54 EPS
Current Dividend Information for Baxalta (NYSE:BXLT)
|Most Recent Dividend:||7/1/2016|
|Dividend Growth:||0.00% (3 Year Average)|
|Payout Ratio:||0.00% (Based on This Year's Estimates)|
0.00% (Based on Next Year's Estimates)
Dividend History by Quarter for Baxalta (NYSE:BXLT)
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Insider Trading and Institutional Ownership History for Baxalta (NYSE:BXLT)Insider Trades by Quarter for Baxalta (NYSE:BXLT)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|3/24/2016||Albert P L Stroucken||Director||Sell||5,660||$39.98||$226,286.80|| |
|2/25/2016||Blake E Devitt||Director||Buy||5,900||$39.17||$231,103.00|| |
Headline Trends for Baxalta (NYSE:BXLT)
Latest Headlines for Baxalta (NYSE:BXLT)
Baxalta (BXLT) Chart for Tuesday, May, 23, 2017